
Claims

1. Compound of Formula VI:



(VI)

2-[4-(cyclopropylmethylsulfinyl)phenyl]-N-[4-[1-(difluoromethyl)-2,2,2-trifluoro-1-hydroxy-ethyl]phenyl]acetamide;
(-)-2-[4-[(S)-cyclopropylmethylsulfinyl]phenyl]-N-[4-[(1R)-1-(difluoromethyl)-2,2,2-trifluoro-1-hydroxy-ethyl]phenyl]acetamide;
(-)-2-[4-[(S)-cyclopropylmethylsulfinyl]phenyl]-N-[4-[(1S)-1-(difluoromethyl)-2,2,2-trifluoro-1-hydroxy-ethyl]phenyl]acetamide;
(+)-2-[4-[(R)-cyclopropylmethylsulfinyl]phenyl]-N-[4-[(1R)-1-(difluoromethyl)-2,2,2-trifluoro-1-hydroxy-ethyl]phenyl]acetamide;
(+)-2-[4-[(R)-cyclopropylmethylsulfinyl]phenyl]-N-[4-[(1S)-1-(difluoromethyl)-2,2,2-trifluoro-1-hydroxy-ethyl]phenyl]acetamide,
or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 or a pharmaceutically acceptable salt thereof for use in therapy.

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof for use in the treatment of RORγ-mediated autoimmune diseases and RORγ-mediated respiratory diseases.

4. A compound according to claim 1 or a pharmaceutically acceptable salt thereof for use in the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, Crohn's disease and multiple sclerosis.

5. The compound according to claim 1 for use in the treatment of RORγ-mediated osteoarthritis or RORγ-mediated asthma.

6. The compound according to claim 1 for use in the treatment of RORγ-mediated mucosal leishmaniasis.

7. The compound according to claim 1 for use in the treatment of RORγ-mediated Kawasaki disease or RORγ-mediated Hashimoto's thyroiditis.

8. Medicament characterized in that it comprises a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition, which comprises a compound according to claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.

10. A pharmaceutical composition according to claim 9 which further comprises at least one additional therapeutically active agent.